In men with prostate cancer, it is often difficult to tell which drugs might be most effective against prostate cancer cells. The purpose of this study is to see how one drug, degarelix, affects the prostate gland.
Degarelix is used to treat prostate cancer by lowering the levels of cancer-fueling testosterone in the body. In this study, patients will take degarelix four or seven days before prostate cancer surgery. After doctors remove the prostate gland, it will be examined to see what effect degarelix has had on prostate cancer cells.
Doctors do not expect patients in this study to benefit directly from degarelix, since the prostate will be removed shortly afterward. Instead, doctors hope to better understand how degarelix works on prostate cancer cells and to use this information to develop additional prostate cancer treatments in the future.